CINECA IRIS Institutional Research Information System

VIOLA, DAVID
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.299
EU - Europa 4.049
AS - Asia 3.760
SA - Sud America 546
AF - Africa 249
Continente sconosciuto - Info sul continente non disponibili 230
OC - Oceania 10
Totale 16.143
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.098
DE - Germania 1.332
SG - Singapore 1.175
CN - Cina 1.044
IT - Italia 756
HK - Hong Kong 607
SE - Svezia 574
BR - Brasile 428
GB - Regno Unito 389
VN - Vietnam 312
BG - Bulgaria 235
AT - Austria 158
FR - Francia 147
RU - Federazione Russa 146
CA - Canada 134
TR - Turchia 132
CI - Costa d'Avorio 120
IN - India 120
FI - Finlandia 102
JP - Giappone 101
BD - Bangladesh 57
SN - Senegal 57
AR - Argentina 41
NL - Olanda 37
KR - Corea 34
MX - Messico 27
UA - Ucraina 27
IQ - Iraq 26
PL - Polonia 26
ZA - Sudafrica 23
EC - Ecuador 19
SA - Arabia Saudita 19
ES - Italia 18
MA - Marocco 18
BE - Belgio 17
CH - Svizzera 17
PK - Pakistan 17
CO - Colombia 16
ID - Indonesia 15
UZ - Uzbekistan 13
JM - Giamaica 12
PH - Filippine 12
VE - Venezuela 12
IR - Iran 11
LT - Lituania 11
UY - Uruguay 10
IE - Irlanda 9
TN - Tunisia 9
AU - Australia 8
JO - Giordania 8
GR - Grecia 7
MY - Malesia 7
AZ - Azerbaigian 6
CL - Cile 6
EG - Egitto 6
HU - Ungheria 6
PY - Paraguay 6
DK - Danimarca 5
LB - Libano 5
PT - Portogallo 5
SK - Slovacchia (Repubblica Slovacca) 5
TW - Taiwan 5
BO - Bolivia 4
CZ - Repubblica Ceca 4
IL - Israele 4
NG - Nigeria 4
NP - Nepal 4
OM - Oman 4
PA - Panama 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BY - Bielorussia 3
EE - Estonia 3
GA - Gabon 3
HN - Honduras 3
KE - Kenya 3
KZ - Kazakistan 3
LK - Sri Lanka 3
PE - Perù 3
RO - Romania 3
AO - Angola 2
BH - Bahrain 2
BZ - Belize 2
CR - Costa Rica 2
CY - Cipro 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EU - Europa 2
KG - Kirghizistan 2
MN - Mongolia 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
A1 - Anonimo 1
BB - Barbados 1
BS - Bahamas 1
CW - ???statistics.table.value.countryCode.CW??? 1
DM - Dominica 1
ET - Etiopia 1
Totale 15.904
Salva come PNG Salva come JPEG
Città #
Ashburn 852
Singapore 618
Hong Kong 593
Woodbridge 508
Chandler 506
Fairfield 447
Dallas 441
San Jose 418
Santa Clara 412
Houston 352
Ann Arbor 267
Shanghai 237
Sofia 235
Beijing 228
Seattle 220
Milan 215
Wilmington 206
New York 200
Cambridge 162
Vienna 139
Princeton 131
Los Angeles 130
London 123
Abidjan 120
Boardman 110
Lawrence 95
Lauterbourg 90
Munich 88
Tokyo 86
Ho Chi Minh City 82
Ottawa 82
Medford 75
Florence 63
Serra 60
Boulder 58
Des Moines 58
Dakar 57
Frankfurt am Main 52
Council Bluffs 48
Izmir 48
Dearborn 46
Istanbul 46
Nanjing 44
Hanoi 43
Redondo Beach 43
Bremen 40
Hefei 40
Rome 40
Pisa 39
Dong Ket 36
São Paulo 36
Buffalo 35
San Diego 34
Helsinki 27
Nürnberg 26
Seoul 25
Orem 23
Columbus 22
Fuzhou 22
Turku 22
Düsseldorf 20
Belo Horizonte 19
Amsterdam 18
Atlanta 17
Jacksonville 17
Redwood City 17
Brussels 16
Changsha 16
Montreal 16
Quanzhou 16
Guangzhou 15
Lancaster 15
Phoenix 15
Redmond 15
Rio de Janeiro 15
Zhengzhou 15
Denver 14
Dhaka 14
Ogden 14
San Francisco 14
Washington 14
Jiaxing 13
Toronto 13
Ankara 12
Chicago 12
Nanchang 12
Johannesburg 11
Kunming 11
Norwalk 11
Tashkent 11
Tianjin 11
Warsaw 11
Baghdad 10
Brasília 10
Chengdu 10
Riyadh 10
Shenyang 10
Stockholm 10
The Dalles 10
Wuhan 10
Totale 10.141
Salva come PNG Salva come JPEG
Nome #
Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy 323
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 261
null 259
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 246
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 238
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 234
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 233
Targeted Therapy in Thyroid Cancer: State of the Art 225
Incidental versus clinically evident thyroid cancer: A 5-year follow-up study 222
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 220
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 217
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 216
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study 209
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 205
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 204
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 203
Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years. 202
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 199
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 197
DIAGNOSTIC AND THERAPEUTIC ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 195
Il carcinoma tiroideo: nuove prospettive terapeutiche. 193
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 189
Role Of Prophylactic Central Compartment Lymph Node Dissection On The Outcome Of Patients With Papillary Thyroid Carcinoma And Synchronous Ipsilateral Cervical Lymph Node Metastases 189
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 187
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 186
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 179
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 178
BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. 177
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 177
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 177
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 177
Role of YAP-1 in Thyroid Tumor Progression and Outcome 175
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 171
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 171
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 170
Tall cell percentage alone in PTC without aggressive features should not guide patients’ clinical management 170
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 167
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 167
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer 167
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 165
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 164
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 164
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 164
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 163
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 163
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 162
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 161
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 158
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 157
Papillary Thyroid Carcinoma With Rare exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience 154
Infertility in a patient with papillary thyroid carcinoma treated with high doses of 131-I. 152
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 149
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 149
null 146
Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer 145
BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid cancer 145
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 144
An idic(15) associated with POF (premature ovarian failure): Molecular cytogenetic definition of a case and review of the literature. 143
Medullary thyroid carcinoma in children 141
Cabozantinib: An orphan drug for thyroid cancer 139
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 139
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 139
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 135
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 135
Protocolli gestionali-diagnostico-terapeutico-assistenziali in chirurgica tiroidea. 2° Consensus Conference. 133
BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma 132
Management of Medullary Thyroid Cancer 131
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 131
The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer 129
Proteinuria is a late-onset adverse event in patients treated with cabozantinib 128
La tiroide come sede di metastasi 127
Short term follow-up outcome of stage I thyroid cancer patients is worst when BRAFV600E mutation is present in the primary tumor. 127
BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment 126
BRAFV600E mutation is an indipendent bad prognostic factor for the out come of patients with papillary thyroid carcinoma: a 15-year median follow-up study. 125
The Integrity of Tumor Capsule Identifies a Subgroup of Indolent Cases Not Only Among the Follicular (FVPTC) But Also in Classic Variant of Papillary Thyroid Cancer (CVPTC) 125
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study 124
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 119
. Utilità della ricerca della mutazione di BRAF nel tumore primitivo di pazienti affetti da carcinoma papillare della tiroide a basso rischio. 118
Follicular (FVPTC) VS Classical (CVPTC) variant of papillary thyroid cancer: correlation of the outcome after 12 years of follow up. 117
BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer 114
Targeted therapies for thyroid cancer. 113
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 112
null 110
null 107
null 105
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. 103
Biological and molecular markers for diagnosis, follow-up and prognosis of patients affected by thyroid cancer. 99
KIF5B/RET rearrangement in diffuse sclerosing variant of papillary thyroid cancer (DSV-PTC) 98
null 86
null 86
Incidental versus clinically evident thyroid cancer: A 5-year follow-up study. 86
null 84
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer 83
Ret Oncogene and Thyroid Carcinoma 83
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. 81
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA) 79
null 79
BRAF(V600E) mutations are correlated with a lower expression of both NIS and TPO mRNA expression in papillary thyroid cancer (PTC) 77
Long Term Outcomes of Patients Undergoing Ablation With Low Activities of RAI. 74
Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants 72
Totale 15.474
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.756
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.756
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.075 0 39 22 62 229 159 33 46 59 46 77 303
2022/20231.835 207 310 154 150 163 201 35 138 333 13 118 13
2023/20241.022 116 104 124 69 132 198 64 19 17 18 53 108
2024/20253.298 38 134 40 184 365 294 226 148 387 463 296 723
2025/20263.745 325 504 417 341 418 296 516 155 230 344 149 50
2026/2027120 78 42 0 0 0 0 0 0 0 0 0 0
Totale 16.143